Key Takeaways
- With Trump’s return, pharma trades a disagreeable White House for an unpredictable one.
- The nomination of Robert F. Kennedy Jr. to run HHS creates an unprecedented challenge for industry, especially in the upcoming user fee renewal negotiations.
- Republican control of Congress offers a favorable environment for many pharma priorities, but also will increase pressure to decouple the supply chain from China.
If the pharmaceutical industry were to conjure a list of fears about what may happen to their US businesses during a democratic administration, Joe Biden’s four years in the White...
Price controls? Check. Declining stock prices even as the broader market grows? Check. Antitrust investigations aimed at limiting partnering and promotional options? Check and check.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?